On March 9, 2022 SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and ImaginAb Inc. (ImaginAb), a market-leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and therapeutic radiopharmaceuticals (RPT), reported the signing of a clinical supply agreement (Press release, Shine Medical Technologies, MAR 9, 2022, View Source [SID1234609771]). Under the terms of this agreement, SHINE will provide ImaginAb with highly pure, non-carrier-added (n.c.a.) lutetium-177 (Lu-177) to support the company’s preclinical and clinical needs in the development of RPTs targeting various cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are thrilled to continue to partner with leading biotechnology companies like ImaginAb in the mission to drive innovation of cancer therapeutics," said Greg Piefer, SHINE’s founder and CEO. "We are proud to deliver Lu-177 and other medical isotopes as they play a major role for biotechnology companies like ImaginAb to continue to innovate treatment solutions for critically ill patients."
SHINE’s Therapeutics division produces n.c.a. Lu-177, a low-energy beta-particle emitter, which can be paired with a targeting molecule (such as an antibody or peptide) to directly target and irradiate cancer cells. SHINE’s fusion technology and proprietary medical isotope production is expected to scale without supply chain limitations experienced recently due to nuclear reactor shutdowns. The result: better meeting the needs of n.c.a. Lu-177 based therapies as they commercialize.
ImaginAb is developing radiopharmaceutical therapy agents based on proprietary minibody and cys-diabody platform technologies. This platform possesses the highly tumor target selective features of larger antibodies while offering highly tunable pharmacokinetics providing rapid clearance from non-target tissues.
Ian Wilson, CEO of ImaginAb, commented: "Having a robust supply chain is key to the implementation of radiopharmaceutical therapy, and partnering with SHINE for our Lu-177 supply offers access to what we feel will become one of the largest and most reliable sources in the world for this isotope. Lu-177 is a great fit for our platform technologies. We are very excited about our upcoming clinical programs in oncology radiopharmaceutical therapies."
SHINE will begin supplying ImaginAb with n.c.a. Lu-177 immediately for the company’s development activities and for therapeutic clinical trials planned for 2023. More information on clinical trial results will be provided directly by ImaginAb.